The Experts below are selected from a list of 315 Experts worldwide ranked by ideXlab platform

Peter M. Vogt - One of the best experts on this subject based on the ideXlab platform.

  • High-energy focussed extracorporeal shockwave therapy reduces pain in Plantar Fibromatosis (Ledderhose’s disease)
    BMC Research Notes, 2012
    Co-Authors: Karsten Knobloch, Peter M. Vogt
    Abstract:

    Background Plantar Fibromatosis is a benign disease creating nodules on the medial Plantar side of affected patients. While surgical removal is regarded as the therapeutic mainstay, recurrence rates and impairment of daily activities remains substantial. High-energy focussed extracorporeal shockwave therapy has been suggested to be potentially effective in Plantar Fibromatosis in terms of pain reduction.

  • high energy focussed extracorporeal shockwave therapy reduces pain in Plantar Fibromatosis ledderhose s disease
    BMC Research Notes, 2012
    Co-Authors: Karsten Knobloch, Peter M. Vogt
    Abstract:

    Background Plantar Fibromatosis is a benign disease creating nodules on the medial Plantar side of affected patients. While surgical removal is regarded as the therapeutic mainstay, recurrence rates and impairment of daily activities remains substantial. High-energy focussed extracorporeal shockwave therapy has been suggested to be potentially effective in Plantar Fibromatosis in terms of pain reduction.

  • High-energy focussed extracorporeal shockwave therapy reduces pain in Plantar Fibromatosis (Ledderhose’s disease)
    BMC Research Notes, 2012
    Co-Authors: Karsten Knobloch, Peter M. Vogt
    Abstract:

    Background Plantar Fibromatosis is a benign disease creating nodules on the medial Plantar side of affected patients. While surgical removal is regarded as the therapeutic mainstay, recurrence rates and impairment of daily activities remains substantial. High-energy focussed extracorporeal shockwave therapy has been suggested to be potentially effective in Plantar Fibromatosis in terms of pain reduction. Hypothesis High-energy focussed extracorporeal shockwave therapy reduces pain in Plantar Fibromatosis. Findings A total number of six patients (5 males, 58±4 years) were included with Plantar Fibromatosis (Ledderhose’s disease) associated with pain. Three patients were operated on previously, one had concomitant Dupuytren’s contracture. High-energy focussed ESWT was applied using a Storz Duolith SD1 (2000 impulses, 3 Hz, 1.24 mJ/mm2) in two sessions with 7 days between. Pain was 6±2 at baseline, 2±1 after 14 days and 1±1 after 3 months. Softening of the nodules was noted by all patients. No adverse effects were noted. Conclusions High-energy focussed extracorporeal shockwave energy reduces pain in painful Plantar Fibromatosis (Morbus Ledderhose). Further large-scale prospective trials are warranted to elucidate the value of high-energy focussed extracorporeal shockwave therapy (ESWT) in Plantar Fibromatosis in terms of recurrence and efficacy.

Yong-taek Lee - One of the best experts on this subject based on the ideXlab platform.

  • Follow-up of clinical and sonographic features after extracorporeal shock wave therapy in painful Plantar Fibromatosis.
    PloS one, 2020
    Co-Authors: Jin Tae Hwang, Kyung Jae Yoon, Chul-hyun Park, Jae Hyeoung Choi, Hee-jin Park, Young Sook Park, Yong-taek Lee
    Abstract:

    Background: Extracorporeal shock wave therapy (ESWT) has been used as a safe alternative treatment for refractory musculoskeletal diseases, such as Plantar fasciitis, Achilles tendinopathy and gluteal tendinopathy, and various forms of Fibromatosis including palmar or penile Fibromatosis. However, there is limited published data for clinical and sonographic features of Plantar Fibromatosis after ESWT. The purpose of this study was to evaluate the long-term clinical outcome of ESWT in ultrasonography-confirmed Plantar Fibromatosis and ultrasonographic changes of Plantar fibroma after ESWT. Methods: Medical charts of 26 patients (30 feet) with Plantar Fibromatosis confirmed by ultrasonography were reviewed. Finally, a total of 10 feet who underwent ESWT for “Poor” or “Fair” grade of Roles-Maudsley Score (RMS) and symptoms persisted for >6 months were included in this study. Short-term follow-up was conducted one week after ESWT and long-term follow-up time averaged 34.0 months. The Numerical Rating Scale (NRS) and RMS were collected for the evaluation of clinical features. Follow-up ultrasonography was conducted at long-term follow-up and changes of Plantar fibroma was assessed. A greater than 50% reduction in the NRS and achievement of a “good” or “excellent” grade in the RMS were regarded as treatment success. Additionally, medical charts of 144 patients (168 feet) with Plantar fasciitis confirmed by ultrasonography were reviewed and subsequently, 42 feet who underwent ESWT with the same protocol were included for the comparison of clinical features. Results: In Plantar Fibromatosis, baseline NRS (6.2 ± 1.3) and RMS (3.5 ± 0.5) were significantly improved at short-term follow-up (NRS, 1.8 ± 1.0; RMS, 2.0 ± 0.8, P

  • follow up of clinical and sonographic features after extracorporeal shock wave therapy in painful Plantar Fibromatosis
    PLOS ONE, 2020
    Co-Authors: Jin Tae Hwang, Kyung Jae Yoon, Chul-hyun Park, Jae Hyeoung Choi, Hee-jin Park, Young Sook Park, Yong-taek Lee
    Abstract:

    BACKGROUND Extracorporeal shock wave therapy (ESWT) has been used as a safe alternative treatment for refractory musculoskeletal diseases, such as Plantar fasciitis, Achilles tendinopathy and gluteal tendinopathy, and various forms of Fibromatosis including palmar or penile Fibromatosis. However, there is limited published data for clinical and sonographic features of Plantar Fibromatosis after ESWT. The purpose of this study was to evaluate the long-term clinical outcome of ESWT in ultrasonography-confirmed Plantar Fibromatosis and ultrasonographic changes of Plantar fibroma after ESWT. METHODS Medical charts of 26 patients (30 feet) with Plantar Fibromatosis confirmed by ultrasonography were reviewed. Finally, a total of 10 feet who underwent ESWT for "Poor" or "Fair" grade of Roles-Maudsley Score (RMS) and symptoms persisted for >6 months were included in this study. Short-term follow-up was conducted one week after ESWT and long-term follow-up time averaged 34.0 months. The Numerical Rating Scale (NRS) and RMS were collected for the evaluation of clinical features. Follow-up ultrasonography was conducted at long-term follow-up and changes of Plantar fibroma was assessed. A greater than 50% reduction in the NRS and achievement of a "good" or "excellent" grade in the RMS were regarded as treatment success. Additionally, medical charts of 144 patients (168 feet) with Plantar fasciitis confirmed by ultrasonography were reviewed and subsequently, 42 feet who underwent ESWT with the same protocol were included for the comparison of clinical features. RESULTS In Plantar Fibromatosis, baseline NRS (6.2 ± 1.3) and RMS (3.5 ± 0.5) were significantly improved at short-term follow-up (NRS, 1.8 ± 1.0; RMS, 2.0 ± 0.8, P < .001, respectively) and long-term follow-up (NRS, 0.6 ± 1.1; RMS, 1.4 ± 0.8, P < .001, respectively). Treatment success was recorded in seven feet (70.0%) at short-term follow-up and 8 feet (80%) at long-term follow-up, which is comparable to that of the Plantar fasciitis group (28 feet, 66.7%; 35 feet, 83.3%, respectively). In long-term follow-up ultrasonography, mean fibroma thickness was reduced from 4.4±1.0 to 2.6±0.8 mm (P = .003); however, length and width were not significantly changed. There were no serious adverse effects. CONCLUSION While these are preliminary findings, and must be confirmed in a randomized placebo control study, ESWT can have a beneficial long-term effect on pain relief and functional outcomes in painful Plantar Fibromatosis. However, ESWT is unlikely to affect the ultrasonographic morphology of Plantar fibroma, with the exception of reducing the thickness. LEVEL OF EVIDENCE Level III, retrospective cohort study.

Karsten Knobloch - One of the best experts on this subject based on the ideXlab platform.

  • High-energy focussed extracorporeal shockwave therapy reduces pain in Plantar Fibromatosis (Ledderhose’s disease)
    BMC Research Notes, 2012
    Co-Authors: Karsten Knobloch, Peter M. Vogt
    Abstract:

    Background Plantar Fibromatosis is a benign disease creating nodules on the medial Plantar side of affected patients. While surgical removal is regarded as the therapeutic mainstay, recurrence rates and impairment of daily activities remains substantial. High-energy focussed extracorporeal shockwave therapy has been suggested to be potentially effective in Plantar Fibromatosis in terms of pain reduction.

  • high energy focussed extracorporeal shockwave therapy reduces pain in Plantar Fibromatosis ledderhose s disease
    BMC Research Notes, 2012
    Co-Authors: Karsten Knobloch, Peter M. Vogt
    Abstract:

    Background Plantar Fibromatosis is a benign disease creating nodules on the medial Plantar side of affected patients. While surgical removal is regarded as the therapeutic mainstay, recurrence rates and impairment of daily activities remains substantial. High-energy focussed extracorporeal shockwave therapy has been suggested to be potentially effective in Plantar Fibromatosis in terms of pain reduction.

  • High-energy focussed extracorporeal shockwave therapy reduces pain in Plantar Fibromatosis (Ledderhose’s disease)
    BMC Research Notes, 2012
    Co-Authors: Karsten Knobloch, Peter M. Vogt
    Abstract:

    Background Plantar Fibromatosis is a benign disease creating nodules on the medial Plantar side of affected patients. While surgical removal is regarded as the therapeutic mainstay, recurrence rates and impairment of daily activities remains substantial. High-energy focussed extracorporeal shockwave therapy has been suggested to be potentially effective in Plantar Fibromatosis in terms of pain reduction. Hypothesis High-energy focussed extracorporeal shockwave therapy reduces pain in Plantar Fibromatosis. Findings A total number of six patients (5 males, 58±4 years) were included with Plantar Fibromatosis (Ledderhose’s disease) associated with pain. Three patients were operated on previously, one had concomitant Dupuytren’s contracture. High-energy focussed ESWT was applied using a Storz Duolith SD1 (2000 impulses, 3 Hz, 1.24 mJ/mm2) in two sessions with 7 days between. Pain was 6±2 at baseline, 2±1 after 14 days and 1±1 after 3 months. Softening of the nodules was noted by all patients. No adverse effects were noted. Conclusions High-energy focussed extracorporeal shockwave energy reduces pain in painful Plantar Fibromatosis (Morbus Ledderhose). Further large-scale prospective trials are warranted to elucidate the value of high-energy focussed extracorporeal shockwave therapy (ESWT) in Plantar Fibromatosis in terms of recurrence and efficacy.

Joseph Mantil - One of the best experts on this subject based on the ideXlab platform.

  • increased f 18 fdg uptake on positron emission tomography computed tomography imaging caused by Plantar Fibromatosis
    Clinical Nuclear Medicine, 2008
    Co-Authors: Jennifer Scheler, Bhavya Rehani, Thomas Percy, Richard Pelstring, Ankur Bharija, Donald Ames, Joseph Mantil
    Abstract:

    We detail the history and evaluation of a 68-year-old man who had head-to-toe PET/CT scanning that showed a focal area of increased FDG uptake in the left medial foot. This was thought to be recurrence of his melanoma. The patient was asymptomatic. He had a history of malignant melanoma of the right ear, which was removed in 2001. On biopsy, the foot lesion was diagnosed as Plantar Fibromatosis. Plantar Fibromatosis is a benign fibroblastic condition, which can be indistinguishable from malignancy in head-to-toe PET/CT scans. Awareness of their potential appearance on PET and PET/CT will aid in the appropriate staging of oncology patients.

  • Increased F-18 FDG uptake on positron emission tomography/computed tomography imaging caused by Plantar Fibromatosis.
    Clinical nuclear medicine, 2008
    Co-Authors: Jennifer Scheler, Bhavya Rehani, Thomas Percy, Richard Pelstring, Ankur Bharija, Donald Ames, Joseph Mantil
    Abstract:

    We detail the history and evaluation of a 68-year-old man who had head-to-toe PET/CT scanning that showed a focal area of increased FDG uptake in the left medial foot. This was thought to be recurrence of his melanoma. The patient was asymptomatic. He had a history of malignant melanoma of the right ear, which was removed in 2001. On biopsy, the foot lesion was diagnosed as Plantar Fibromatosis. Plantar Fibromatosis is a benign fibroblastic condition, which can be indistinguishable from malignancy in head-to-toe PET/CT scans. Awareness of their potential appearance on PET and PET/CT will aid in the appropriate staging of oncology patients.

Jin Tae Hwang - One of the best experts on this subject based on the ideXlab platform.

  • Follow-up of clinical and sonographic features after extracorporeal shock wave therapy in painful Plantar Fibromatosis.
    PloS one, 2020
    Co-Authors: Jin Tae Hwang, Kyung Jae Yoon, Chul-hyun Park, Jae Hyeoung Choi, Hee-jin Park, Young Sook Park, Yong-taek Lee
    Abstract:

    Background: Extracorporeal shock wave therapy (ESWT) has been used as a safe alternative treatment for refractory musculoskeletal diseases, such as Plantar fasciitis, Achilles tendinopathy and gluteal tendinopathy, and various forms of Fibromatosis including palmar or penile Fibromatosis. However, there is limited published data for clinical and sonographic features of Plantar Fibromatosis after ESWT. The purpose of this study was to evaluate the long-term clinical outcome of ESWT in ultrasonography-confirmed Plantar Fibromatosis and ultrasonographic changes of Plantar fibroma after ESWT. Methods: Medical charts of 26 patients (30 feet) with Plantar Fibromatosis confirmed by ultrasonography were reviewed. Finally, a total of 10 feet who underwent ESWT for “Poor” or “Fair” grade of Roles-Maudsley Score (RMS) and symptoms persisted for >6 months were included in this study. Short-term follow-up was conducted one week after ESWT and long-term follow-up time averaged 34.0 months. The Numerical Rating Scale (NRS) and RMS were collected for the evaluation of clinical features. Follow-up ultrasonography was conducted at long-term follow-up and changes of Plantar fibroma was assessed. A greater than 50% reduction in the NRS and achievement of a “good” or “excellent” grade in the RMS were regarded as treatment success. Additionally, medical charts of 144 patients (168 feet) with Plantar fasciitis confirmed by ultrasonography were reviewed and subsequently, 42 feet who underwent ESWT with the same protocol were included for the comparison of clinical features. Results: In Plantar Fibromatosis, baseline NRS (6.2 ± 1.3) and RMS (3.5 ± 0.5) were significantly improved at short-term follow-up (NRS, 1.8 ± 1.0; RMS, 2.0 ± 0.8, P

  • follow up of clinical and sonographic features after extracorporeal shock wave therapy in painful Plantar Fibromatosis
    PLOS ONE, 2020
    Co-Authors: Jin Tae Hwang, Kyung Jae Yoon, Chul-hyun Park, Jae Hyeoung Choi, Hee-jin Park, Young Sook Park, Yong-taek Lee
    Abstract:

    BACKGROUND Extracorporeal shock wave therapy (ESWT) has been used as a safe alternative treatment for refractory musculoskeletal diseases, such as Plantar fasciitis, Achilles tendinopathy and gluteal tendinopathy, and various forms of Fibromatosis including palmar or penile Fibromatosis. However, there is limited published data for clinical and sonographic features of Plantar Fibromatosis after ESWT. The purpose of this study was to evaluate the long-term clinical outcome of ESWT in ultrasonography-confirmed Plantar Fibromatosis and ultrasonographic changes of Plantar fibroma after ESWT. METHODS Medical charts of 26 patients (30 feet) with Plantar Fibromatosis confirmed by ultrasonography were reviewed. Finally, a total of 10 feet who underwent ESWT for "Poor" or "Fair" grade of Roles-Maudsley Score (RMS) and symptoms persisted for >6 months were included in this study. Short-term follow-up was conducted one week after ESWT and long-term follow-up time averaged 34.0 months. The Numerical Rating Scale (NRS) and RMS were collected for the evaluation of clinical features. Follow-up ultrasonography was conducted at long-term follow-up and changes of Plantar fibroma was assessed. A greater than 50% reduction in the NRS and achievement of a "good" or "excellent" grade in the RMS were regarded as treatment success. Additionally, medical charts of 144 patients (168 feet) with Plantar fasciitis confirmed by ultrasonography were reviewed and subsequently, 42 feet who underwent ESWT with the same protocol were included for the comparison of clinical features. RESULTS In Plantar Fibromatosis, baseline NRS (6.2 ± 1.3) and RMS (3.5 ± 0.5) were significantly improved at short-term follow-up (NRS, 1.8 ± 1.0; RMS, 2.0 ± 0.8, P < .001, respectively) and long-term follow-up (NRS, 0.6 ± 1.1; RMS, 1.4 ± 0.8, P < .001, respectively). Treatment success was recorded in seven feet (70.0%) at short-term follow-up and 8 feet (80%) at long-term follow-up, which is comparable to that of the Plantar fasciitis group (28 feet, 66.7%; 35 feet, 83.3%, respectively). In long-term follow-up ultrasonography, mean fibroma thickness was reduced from 4.4±1.0 to 2.6±0.8 mm (P = .003); however, length and width were not significantly changed. There were no serious adverse effects. CONCLUSION While these are preliminary findings, and must be confirmed in a randomized placebo control study, ESWT can have a beneficial long-term effect on pain relief and functional outcomes in painful Plantar Fibromatosis. However, ESWT is unlikely to affect the ultrasonographic morphology of Plantar fibroma, with the exception of reducing the thickness. LEVEL OF EVIDENCE Level III, retrospective cohort study.